Acute pulmonary embolism in patients presenting pulmonary deterioration after admission to internal medicine wards for non-critical COVID-19.

Heman POLO FRIZ (polofriz@libero.it)
Internal Medicine, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Elia GELFI
Internal Medicine, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Annalisa ORENTI
Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy.

Elena MOTTO
Internal Medicine, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Laura PRIMITZ
Internal Medicine, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Tino DONZELLI
Internal Medicine, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Marcello INTOTERO
Radiology, Diagnostic Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Paolo SCARPAZZA
Pulmonology, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Giuseppe VIGHI
Internal Medicine, Medical Department, Vimercate Hospital, ASST Vimercate, Vimercate, Italy.

Claudio CIMMINIELLO
Research and Study Center of the Italian Society of Angiology and Vascular Pathology (Società Italiana di Angiologia e Patologia Vascolare, SIAPAV), Milan, Italy.

Patrizia BORACCHI
Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy.

Research Article

Keywords: COVID-19, venous thromboembolism, pulmonary embolism, D-dimer, CT Angiography.

DOI: https://doi.org/10.21203/rs.3.rs-73601/v2
Abstract

INTRODUCTION. Emerging evidence associates COVID-19 to an increased risk of acute pulmonary embolism (APE). The present study aimed to assess the prevalence of APE in patients admitted to internal medicine department wards for non-critical COVID-19 who presented clinical deterioration, and to investigate the association of clinical and biochemical variables with a confirmed diagnosis of APE in these subjects.

METHODS. All consecutive patients admitted to the internal medicine department of a general hospital with a diagnosis of non-critical COVID-19, who performed a Computer Tomography Pulmonary Angiography (CTPA) for respiratory deterioration in April 2020, were included in this retrospective cohort study.

RESULTS. Study populations: 41 subjects, median (IRQ) age: 71.7 (63-76) years, CPTA confirmed APE=8 (19.51%, CI95%: 8.82%-34.87%). Among patients with and without APE, no significant differences were found with regards symptoms, comorbidities, treatment, Wells score and outcomes. The optimal cut-off value of D-dimer for predicting APE was 2454 ng/mL, sensitivity (CI95%): 63 (24-91), specificity: 73 (54-87), Positive Predictive Value: 36 (13-65), Negative Predictive Value: 89 (71-98) and AUC: 0.62 (0.38-0.85). The standard and age-adjusted D-dimer cut-offs, and the Wells score ≥ 2 did not associate with confirmed APE, albeit a cut-off value of D-dimer=2454 ng/mL showed an RR: 3.21; CI95%: 0.92-13.97; p=0.073.

CONCLUSION. Among patients presenting pulmonary deterioration after admission to internal medicine wards for non-critical COVID-19, the prevalence of APE was high. The traditional diagnostic tools to identify high APE pre-test probability patients does not seem to be clinically useful. These results support the use of a low threshold of suspicion for performing CTPA to exclude or confirm APE as the most appropriate diagnostic approach in this clinical setting.

Introduction

Coronavirus disease (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus – 2 (SARS-CoV-2). The first cases of COVID-19 were reported in the city of Wuhan, China, in December 2019, and in the following weeks the infection spread across China and in other countries, leading to the declaration of pandemic by the World Health Organization [1-2].

The clinical presentation of COVID-19 can be very varied, and encompasses asymptomatic infection, mild illness affecting the upper respiratory tract, and severe pneumonia, which may cause life-threatening respiratory failure [3]. The severity of COVID-19 cases has been classified as mild, moderate, severe, and critical [4].
Emerging evidence suggest that COVID-19 can be complicated by acute pulmonary embolism (APE) [5-7]. Moreover, D-dimer values have been linked to a higher risk of death in patients with COVID-19 [5], and some data suggests that heparin prophylaxis may be associated with better prognosis in COVID-19 patients with severe disease or with markedly elevated D-dimer [8].

Although data from different studies indicate that the incidence of venous thromboembolism (VTE) in COVID-19 patients is higher than that seen in similarly ill hospitalized non COVID-19 subjects, the exact prevalence of APE in COVID-19 patients is not known, and the diagnostic value of D-dimer in subjects with acute SARS-CoV-2 infection is not clear [1,5]. In effect, the increase in mortality associated with elevated D-dimer values in these patients may reflect an increased rate of APE, but it also could be a manifestation of disseminated intravascular coagulation or simply a higher level of systemic inflammation [5,9]. In addition, most of the published studies evaluating thrombotic complications of COVID-19 included intensive care unit (ICU) critical ill patients [8,10-15], and less is known on non-critical subjects admitted to internal medicine department general wards.

The present study aimed to assess the prevalence of APE in patients hospitalized for non-critical COVID-19 in internal medicine department wards, who presented respiratory deterioration after admission, as well as to investigate the association of D-dimer and other clinical and biochemical variables with a confirmed diagnosis of APE in these subjects.

**Materials And Methods**

The study was conducted at the Vimercate Hospital, a 500 bed General Hospital located in Lombardy, northern Italy. From February to May 2020, 712 patients with a confirmed diagnosis of COVID-19 were hospitalized in our institution. Among them, 218 subjects have been admitted to the internal medicine department wards in April 2020.

In the first months of 2020, different reports suggesting an increasing risk of APE in COVID-19 patients were published [6-7]. Thus, in late March, a multidisciplinary group from our hospital issued an internal protocol with some recommendations to prevent and treat thrombotic complications in COVID-19 patients. The protocol strongly recommended performing a diagnostic CTPA to confirm or rule out APE in COVID-19 patients admitted to the internal medicine department wards presenting respiratory deterioration after admission, defined by a PaO2/FiO2 ratio reduction of > 30%.

Therefore, in the present retrospective cohort study we included all COVID-19 patients admitted to the internal medicine department (sub intensive and acute general beds of the internal medicine department wards) who had CTPA examinations performed from April 1st to April 31st for respiratory deterioration after admission, defined by a reduction of > 30% of the PaO2/FiO2 ratio. The exclusion criteria were: subjects with a story of bleeding diathesis and/or current use of anticoagulant therapy before hospitalization; age < 18, and critical COVID19 infection, defined by any of the following criteria a.
respiratory failure needing mechanical assistance, b. shock c. “extra pulmonary” organ failure needing intensive care unit.

Electronic charts of all included patients were retrieved for evaluation. Trained study personnel retrospectively recorded relevant clinical, laboratory and treatment data. The diagnosis of COVID-19 was confirmed by RNA detection of the SARS-CoV-2.

Data of the following laboratory test performed upon admission have been collected: D-dimer, international normalized ratio (INR), c-reactive protein (CRP), white blood cell count (WBCC), lactate dehydrogenase (LDH), alanine transaminase (ALT), aspartate transaminase (ALT), Creatinine (Cr), arterial partial pressure of carbon dioxide (PaCO2), arterial oxygen partial pressure (PaO2), fraction of inspired oxygen (FiO2). Albumin, Interleukin 6, and Antithrombin III were measured within 24 hours of performing CTPA. D-dimer was measured by using HemosIL D-Dimer HS, a latex-enhanced turbidimetric immunoassay from Instrumentation Laboratory, on the fully automated coagulometer ACL TOP analyzer [16]. The normal value declared by the producer is less than 243 ng/mL [16].

Based on a retrospective chart review of clinical symptoms and patient history factors Wells score simplified version was calculated for each patient giving one point for the presence of each of the following items: (1) Previous PE or DVT; (2) Heart rate ≥100 b.p.m.; (3) Surgery or immobilization within the past four weeks; (4) Haemoptysis; (5) Active cancer (6); Clinical signs of DVT ; (7) Alternative diagnosis less likely than PE. Patients with < 2 point were categorized as PE unlikely and those with ≥ 2 points PE likely [17]. Since CTPA was performed in subjects suspected by presenting APE in addition to COVID-19 as causing respiratory deterioration, the last item of Wells score (alternative diagnosis less likely than PE) was considered present (1 point) in all cases.

Pulmonary embolism was confirmed on the basis of the presence of a filling defect in one or more pulmonary arteries up to sub-segmental arteries in CTPA, as stated by certified radiologists belonging to the hospital team, at the time of the acquisition of images. Helical CTPA scans were performed on a Brilliance Philips CT scanner (Philips, Cleveland, OH, USA) which included 64-detector row capability.

This study was conducted in accordance with the amended Declaration of Helsinki. The protocol was approved by to the Local institutional review board, i.e. the Comitato Etico della Provincia Monza e Brianza. Waiver of written informed consent was granted due to the retrospective, observational design.

**Statistical methods**

Clinical characteristics and laboratory data were summarized by number and percentage for categorical variables and by median and interquartile range for numerical variables, in the whole study group and according to APE. To compare the different characteristics among patients with APE confirmed and APE excluded, Fisher exact test was used for categorical variables and Wilcoxon rank rum test was used for numerical variables.
To evaluate the diagnostic accuracy of D-dimer to predict APE, a ROC curve was fitted and the Area Under the ROC Curve (AUC) with pertinent 95% confidence interval (CI95%) was estimated. Optimal cut-off was obtained as the D-dimer value which maximizes both the specificity and the sensitivity. The diagnostic performance of different D-dimer cut-offs (standard cut-off: > 243 ng/mL, age adjusted cut off: patients’ age x 5, ROC curve best discriminating value: 2454 ng/mL) and Wells score (standard cut off: >2) was evaluated by computing the corresponding values of sensitivity and specificity, positive predictive value, negative predictive value with pertinent CI95%. Furthermore, four generalized linear regression models with binomial error and link log were fitted: the response was APE and the explanatory variable was a dichotomous variable discriminating patients with D-dimer value over the different cut offs or Wells score over 2. Results were reported as Relative Risk (RR) with corresponding CI95% and p-values.

All analyses were performed using R software version 4.0.0, with packages OptimalCutpoints, pROC and epiR added.

Results

From the 1st to 30th April 2020, 41 patients admitted to internal medicine department wards underwent a CTPA because respiratory deterioration after admission, defined by a PaO2/FiO2 ratio reduction of > 30%, and represent the study population. The median (IRQ) age of the cohort was 71.7 (63-76) years, 30 (73%) were females, the median days (IRQ) since onset of symptoms to hospitalization was 8 (4-12) and the median days (IRQ) since onset of symptoms to CTPA was 11 (7-17). By the end of May 2020 in-hospital mortality of the cohort was 4.88%, with 2 patients still hospitalized and 90% already discharged. Clinical characteristics, treatment and outcomes of the study population are shown in Table 1.

The most frequent symptoms were fever (98%), dyspnea (73%) and cough (63%), and more than 70% of subjects were hypertensive (29 cases). Most patients have been treated empirically with hydroxychloroquine (95%) and steroids (80%), more than 70% with full anticoagulant doses of heparin before performing CTPA, and 61% with continuous positive airway pressure.

Eight out of 41 patients (19.51%, CI95%: 8.82% - 34.87%) presented a confirmed APE after performing CTPA. Except for a trend to a higher prevalence of chest pain among subjects with APE, (37% vs. 9%, p = 0.077), no statistically significant differences in patients with and without APE were found, with regards symptoms, comorbidities, treatment, Wells score and outcomes, Table 1. Among patients with confirmed APE a higher median value of white blood cell count (12.4 vs 8.4 *10^9/L, p = 0.007), and a trend for a lower value of alanine aminotransferase were found. The results of laboratory test in patients with APE confirmed and excluded are shown in Table 2.

The median values of D-dimer in patients with APE confirmed and excluded were 3236 and 1056 ug/mL, p = 0.316. The discriminant ability of D-dimer upon admission to identify confirmed vs. non confirmed APE showed an Area Under ROC Curve (AUC) of 0.62 (CI95%: 0.38 - 0.85), Figure 1. The optimal cut-off obtained by the ROC curve was 2454 ng/mL, with values of sensitivity: 63% (CI95%: 24-91%), specificity:
Discussion

Although emerging data suggest that acutely ill patients with COVID-19 have an increased risk for APE, the actual prevalence of APE in this clinical setting is not well known. Most information on the thrombotic complications of COVID-19 derives from studies including critical ill patients admitted to ICUs [8,10-15], and data on non-critical acutely ill subjects are lacking.

In the present study we found that among patients admitted to internal medicine department wards with a diagnosis of non-critical COVID-19, in whom a CTPA was performed because of respiratory deterioration after admission, near 20% presented a confirmed APE. In these subjects the best discriminating cut-off value of D-dimer for predicting APE was approximately 10 fold the standard threshold (2454 ng/mL), showing a trend to be associated with confirmed APE, albeit not statistically significant (RR: 3.21; CI95%: 0.92-13.97; p = 0.073). The values of D-dimer, when the standard and the age adjusted cut-offs were applied, the simplified Wells score, and other laboratory test did not appear to be clinically useful to identify patients with confirmed APE. Moreover, more than 70% have been empirically treated with full anticoagulant doses of heparin before performing CTPA.

Some points are worth discussing.

Firstly, the prevalence of APE we found in this clinical setting was high. This finding is even more noticeable when considering that most patients were receiving heparin at anticoagulant doses. As mentioned, most data on prevalence of APE and thrombotic events in general, are from COVID-19 ICU critical patients [8,10-15]. COVID-19 patients admitted to the ICUs of 3 Dutch hospitals, Klok and colleagues found a cumulative incidence of the composite thromboembolic outcome of 31% (CI95%: 20-41%) with APE representing 81% of all these thrombotic complication (n = 25) [10]. The rate of thromboembolic complications, mainly APE, was higher (11.7%) in COVID-19 patients referred to ICU from a French hospital, than that observed in a historical control group of non-COVID-19 ARDS patients (2.1%) [14]. Among patients with severe COVID-19 infection examined with CTPA in another study [15], 23% [CI95%, 15-33%] presented APE and were more likely to require mechanical ventilation than those without APE. These figures are much higher than the rates of APE observed in non COVID-19 ICU patients with sepsis or shock receiving guideline-recommended thromboprophylaxis [18,19]. In one of the very few
studies which describing thromboembolic events in non ICU COVID-19 patients, Mestre-Gomez et al found that 29 out of 91 subjects (31.9%) who underwent CTPA presented APE, after admission to the internal medicine department [20]. Our results confirm the finding of a high incidence of APE in internal medicine department non-critical COVID-19 patients.

Second, the tools currently used in non COVID-19 patients to estimate the pre-test probability of APE as part of the diagnostic workup (Wells score and standard or age adjusted D-dimer values) seem not to be useful for predicting APE in COVID-19 patients. This was also true for other laboratory test, such as arterial blood gas analysis, interleukin-6, antithrombin III, AST, ALT, LDH, and serum creatinine. Our results suggest that a very high D-dimer cut-off (approximately 10 fold the standard threshold) may be associated to a confirmed APE. These data are in keeping with the results of a recent study reporting that a D-dimer threshold of 2660 μg/L detected all subject with APE among hospitalized COVID-19 patients [21], and in the formerly mentioned study by Mestre-Gomez et al., the best cut-off point was 5000 ug/dL [20]. These cut-off values are much higher than those used to exclude pulmonary embolus in non-ICU patients [22-23]. Even though a diagnostic strategy for APE suspicion based on a single variable (D-dimer) presents evident limitations and guidelines recommend multivariable predicting algorithms [22], the diagnostic value of a sharp increase of D-dimer as marker of increased risk of APE in COVID-19 patients remains to be established. Some authors have proposed using age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients [24]. Yet, in our study the age adjusted threshold did not show to be clinically useful.

Third, in our study most acutely ill patients admitted to the internal medicine department wards with a diagnosis of COVID-19 presenting respiratory deterioration after admission, were under treatment with full anticoagulant doses of heparin before performing CTAP. The fact that these patients have certainly been considered at a very high risk of having APE [25] probably lead physicians to prescribe full anticoagulation instead of prophylaxis with heparin. Interestingly, also in the study by Klok et al [10] it was described as heparin regimes differed between hospitals and the doses increased over time, presumably reflecting an increasing concern on the risk of developing APE in COVID-19 patients. However, empirical use of anticoagulant doses of heparin may not only be ineffective but deleterious since it has been well established that high-dose LMWH administration may be associated with increased incidence of major and fatal bleeding [26]. In fact, pending the results of randomized clinical trials, in patients without a confirmed diagnosis of APE, most authors recommend thromboprophylaxis with LMWH for non-ICU COVID-19 patients [5,27].

Finally, in COVID-19 patients, given the high prevalence of APE, the unavailability of satisfactory tools for estimating pretest probability and the potential high risk of complications associated with the use of empirical anticoagulation, a low threshold for performing CTPA should be strongly recommended. Main contraindications for CTPA are an impaired renal function and hemodynamic instability to undergo the test. Our results show that these conditions are relatively rare among non-ICU COVID-19 patients.
The main limitations of our study are retrospective and monocentric design and small sample size, with large CI95% limiting the precision of estimates and the generalizability of results. Yet, we included all consecutive subjects fulfilling the inclusion criteria, to reduce selection bias. Thus, our study population would represent a real world sample severe COVID-19 patients admitted to internal medicine department wards who presented respiratory deterioration, which lead to perform CTPA. Nevertheless, to confirm our findings, larger and multicenter studies are needed.

**Conclusions**

Among patients admitted to internal medicine department wards with a diagnosis of non-critical COVID-19, in whom a CTPA was performed because of respiratory deterioration after admission, the prevalence of confirmed APE was high (20%).

Some validated tools used in the APE diagnostic workup of non COVID-19 patients, such as D-dimer (standard and age-adjusted cutoffs) and Wells score, along with other commonly used laboratory test, did not seem to be clinically useful to identify patients with confirmed APE.

Most subjects have been treated empirically with full anticoagulant doses of heparin before performing CTPA, even though in many cases CTPA did not confirmed the diagnosis of APE.

While awaiting additional evidence and the development of new diagnostic and therapeutic algorithms, our results support the use of a low threshold of suspicion for performing CTPA to exclude or confirm APE, as the most appropriate diagnostic approach in this clinical setting.

**Declarations**

**Conflict of interest/funding disclosure/authorship**

**Conflict of Interest**: None to declare.

**Writing assistance**: None to declare. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The work has not been published previously and it is not under consideration for publication elsewhere.

**Authorship**: authors declare that all have made substantial contributions to the conception or design of the work, the acquisition, analysis, and the interpretation of data. HPF and EG performed the initial drafting of the work. All authors revised critically the draft adding important intellectual content.

**All authors approve the final version to be published.**

**References**
1. Marietta, M., Coluccio, V. & Luppi, M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med (2020). https://doi.org/10.1007/s11739-020-02432-x

2. Polosa, R., Spinicci, M. & Prisco, D. “COVID-19: diagnosis, management and prognosis”: a new topical collection of Internal and Emergency Medicine. Intern Emerg Med 15, 747–750 (2020). https://doi.org/10.1007/s11739-020-02461-6

3. Cobos-Siles, M., Cubero-Morais, P., Arroyo-Jiménez, I. et al. Cause-specific death in hospitalized individuals infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events. Intern Emerg Med (2020). https://doi.org/10.1007/s11739-020-02485-y

4. China CDC Weekly. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed April 1 2020.

5. Landi, A., De Servi, S. The burden of thrombotic complications in critically ill patients with COVID-19: charting the uncharted. Intern Emerg Med 15, 893–895 (2020). https://doi.org/10.1007/s11739-020-02393-1

6. Danzi GB, Loffi M, Galeazzi G, Gherbesi E (2020) Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. doi:10.1093/eurheartj/ehaa254

7. Xie Y, Wang X, Yang P, Zhang S (2020) COVID-19 Complicated by Acute Pulmonary Embolism. Radiol Cardiothorac Imaging. 2(2):e200067. doi:10.1148/ryct.2020200067

8. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. doi:10.1111/jth.14817

9. Ibañez, C., Perdomo, J., Calvo, A. et al (2020) High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?. J Thromb Thrombolysis https://doi.org/10.1007/s11239-020-02226-0

10. Klok FA, Kuip MJHA, van der Meer NJM, et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. pii: S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013. [Epub ahead of print]

11. Rieder, M., Goller, I., Jeserich, M. et al (2020) Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. J Thromb Thrombolysis https://doi.org/10.1007/s11239-020-02202-8

12. Hasan, S.S., Radford, S., Kow, C.S. et al (2020) Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis https://doi.org/10.1007/s11239-020-02235-z

13. Llitjos JF, Leclerc M, Chochois C, et al (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. doi: 10.1111/jth.14869. [Epub ahead of print].
14. Helms J, Tacquard C, Severac F, et al (2020) CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. doi: 10.1007/s00134-020-06062-x. [Epub ahead of print]

15. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E (2020) Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. Radiology. 201544. doi: 10.1148/radiol.2020201544. [Epub ahead of print]

16. Salvagno GL, Lippi G, Montagnana M, et al. (2008) Performance of the automated and rapid HemosIL D-Dimer HS on the ACL TOP analyzer. Blood Coagul Fibrinolysis. 19(8):817-821. doi:10.1097/MBC.0b013e32830f1bae

17. Gibson NS, Sohne M, Kruip MJ, et al. (2008) Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 99(1):229–234.

18. Kaplan D, Casper TC, Elliott CG, et al. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest. 2015;148(5):1224-1230. doi: 10.1378/chest.15-0287.

19. Zhang C, Zhang Z, Mi J, et al (2019) The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine (Baltimore). 98(23):e15833. doi:10.1097/MD.0000000000015833

20. Mestre-Gómez, B., Lorente-Ramos, R.M., Rogado, J. et al (2020) Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis https://doi.org/10.1007/s11239-020-02190-9

21. Leonard-Lorant I, Delabranche X, Severac F, et al (2020) Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels. Radiology. 201561. doi: 10.1148/radiol.2020201561. [Epub ahead of print]

22. Vedovati MC, Giustozzi M, Franco L (2020) Beyond the guidelines: Novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism. Eur J Intern Med. 72:1-4. doi:10.1016/j.ejim.2019.11.001

23. Robert-Ebadi H, Righini M (2020) The 2019 ESC guidelines on pulmonary embolism: some further insights. Eur J Intern Med. 77:6-8. doi:10.1016/j.ejim.2020.05.007

24. Roncon L, Zuin M, Zonzin P (2020) Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients. Thromb Res. 190:102. doi: 10.1016/j.thromres.2020.04.021. [Epub ahead of print]

25. Spyropoulos AC, Anderson FA, Jr., FitzGerald G, et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 140(3):706-714.

26. Conti CB, Henchi S, Coppeta GP, Testa S, Grassia R (2020) Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?. Eur J Intern Med. 77:147-149. doi:10.1016/j.ejim.2020.05.002

27. Cattaneo M, Bertinato EM, Birocchi S, et al (2020) Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
### TABLE 1. Clinical characteristics of the study population, treatment during hospitalization and outcomes.

| Characteristics                                      | Total (n=41) | APE confirmed (n=8) | APE excluded (n=33) | p value (APE confirmed vs excluded) |
|------------------------------------------------------|--------------|---------------------|---------------------|-------------------------------------|
| **Age, median (IQR)**                                | 71.7 (63 - 76.2) | 67 (57.3 - 74.4) | 72.1 (63.1 - 76.2) | 0.459                               |
| **Female, n (%)**                                    | 30 (73.17%) | 6 (75%)             | 24 (72.73%)         | 1.000                               |
| **Time since onset of symptoms to hospitalization, median days (IQR)** | 8 (4 - 12) | 8.5 (3.5 - 14.8)  | 8 (4 - 12)          | 0.830                               |
| **Time since hospitalization to CTPA, median days (IQR)** | 11 (7 - 17) | 11 (1.2 - 13.5)    | 11 (8 - 17)         | 0.680                               |
| **Symptoms**                                         |              |                     |                     |                                     |
| **Fever, n (%)**                                     | 40 (97.56%) | 8 (100%)            | 32 (96.97%)         | 1.000                               |
| **Cough, n (%)**                                     | 26 (63.41%) | 5 (62.5%)           | 21 (63.64%)         | 1.000                               |
| **Dyspnea, n (%)**                                   | 30 (73.17%) | 4 (50%)             | 26 (78.79%)         | 0.178                               |
| **Chest pain, n (%)**                                | 6 (14.63%)  | 3 (37.5%)           | 3 (9.09%)           | 0.077                               |
| **Diarrhea, n (%)**                                  | 13 (31.71%) | 2 (25%)             | 11 (33.33%)         | 1.000                               |
| **Comorbidities**                                    |              |                     |                     |                                     |
| **Hypertension, n (%)**                              | 29 (70.73%) | 4 (50%)             | 25 (75.76%)         | 0.202                               |
| **Diabetes, n (%)**                                  | 11 (26.83%) | 2 (25%)             | 9 (27.27%)          | 1.000                               |
| **Chronic heart diseases, n (%)**                    | 9 (21.95%)  | 1 (12.5%)           | 8 (24.24%)          | 0.659                               |
| **Active Cancer, n (%)**                             | 3 (7.32%)   | 0 (0%)              | 3 (9.09%)           | 1.000                               |
| **Smoking, n (%)**                                   | 0 (0%)      | 0 (0%)              | 0 (0%)              | 1.000                               |
| **CCI, median (IQR)**                                | 1 (0 - 1)   | 0 (0 - 1)           | 1 (0 - 2)           | 0.173                               |
| **Treatment**                                         |              |                     |                     |                                     |
| **Heparin at prophylactic dose before performing CTPA, n (%)** | 4 (9.76%) | 0 (0%) | 4 (12.12%) | 0.569 |
| **Heparin at anticoagulant dose before performing CTPA, n (%)** | 29 (70.73%) | 5 (62.5%) | 24 (72.73%) | 0.672 |
| **Hydroxychloroquine, n (%)**                        | 39 (95.12%) | 8 (100%)           | 31 (93.94%)         | 1.000                               |
| **Any antiviral therapy, n (%)**                     | 12 (29.27%) | 3 (37.5%)           | 9 (27.27%)          | 0.672                               |
| **Steroids, n (%)**                                  | 33 (80.49%) | 7 (87.5%)           | 26 (78.79%)         | 1.000                               |
| **CPAP, n (%)**                                      | 25 (60.98%) | 5 (62.5%)           | 20 (60.61%)         | 1.000                               |
| **Wells score within 48 hours before CTPA, median (IQR)** | 2 (2 - 2) | 2 (1.8 - 2) | 2 (2 - 2) | 0.681 |
| **Outcome**                                           |              |                     |                     |                                     |
| **Discharged, n (%)**                                | 37 (90.24%) | 7 (87.5%)           | 30 (90.91%)         | 1.000                               |
| **Still hospitalized, n (%)**                        | 2 (4.88%)   | 1 (12.5%)           | 1 (3.03%)           | 1.000                               |
| **In-hospital mortality, n (%)**                     | 2 (4.88%)   | 0 (0%)              | 2 (6.06%)           | 1.000                               |

APE: acute pulmonary embolism. CTPA: computed tomography pulmonary angiography. CCI: Charlson Comorbidities Index. CPAP continuous positive airway pressure.
TABLE 2. Laboratory data in patients with APE confirmed and excluded.

|                         | Normal Range | All patients (n=41) | APE confirmed (n=8) | APE excluded (n=33) | p value (APE confirmed vs excluded) |
|-------------------------|--------------|---------------------|---------------------|---------------------|-----------------------------------|
| D-dimer (ug/mL), median (IQR) | 0 - 243 ug/mL (0) | 1488 (446 - 4211) | 3236 (1943 - 4735) | 1056 (446 - 2634) | 0.316 |
| INR, median (IQR)       | 0.8 - 1.2 (9) | 1.2 (1.1 - 1.3) | 1.2 (1.1 - 1.2) | 1.2 (1.1 - 1.3) | 0.749 |
| Albumin (g/dL), median (IQR) | 3.7 - 5.3 g/dL (10) | 3.0 (2.9 - 3.3) | 2.7 (2.4 - 3.1) | 3.1 (3 - 3.3) | 0.284 |
| CRP (mg/dL), median (IQR) | 0.0 - 8.0 mg/dL (0) | 51 (18 - 140) | 67 (40.2 - 157.8) | 50 (16 - 135) | 0.439 |
| WBCC (*10⁹/L), median (IQR) | 4.0 - 11.0 *10⁹/L (0) | 9.1 (7 - 12.2) | 12.4 (10.4 - 13.4) | 8.4 (6.4 - 10.5) | 0.007 |
| LDH (U/L), median (IQR) | 135 - 225 U/L (1) | 332 (251.8 - 419.2) | 330 (249.2 - 340.8) | 354.5 (251.8 - 441.9) | 0.437 |
| ALT (U/L), median (IQR) | 5 - 43 U/L (1) | 41 (27.8 - 53.2) | 34.5 (23 - 39) | 44.5 (28.8 - 55) | 0.058 |
| AST (U/L), median (IQR) | 3 - 45 U/L (0) | 43.5 (30.8 - 70) | 44 (28 - 58.2) | 43.5 (30.8 - 73.2) | 0.488 |
| Cr (μmol/L), median (IQR) | 0.6 - 1.2 μmol/L (0) | 0.9 (0.8 - 1) | 0.9 (0.8 - 1.1) | 0.8 (0.8 - 1) | 0.383 |
| Interleukin 6 (pg/mL), median (IQR) | < 7 pg/mL (15) | 11.9 (7.8 - 38.7) | 20.8 (10.6 - 37.8) | 11.6 (7 - 35.9) | 0.287 |
| Antithrombin III, median (IQR) | 80 - 120 (19) | 100.5 (90.2 - 114.2) | 89 (88 - 103) | 102 (95 - 115) | 0.456 |
| PaCO2 (mmHg), median (IQR) | 32 - 45 mmHg (0) | 37 (34 - 42) | 42 (38 - 43.2) | 36 (34 - 39) | 0.171 |
| PaO2 (mmHg, median (IQR)) | 83 - 108 mmHg (0) | 95 (71 - 143) | 129 (65.2 - 146.2) | 91 (71 - 139) | 0.934 |
| PaO2/FiO2 ratio, median (IQR) | > 350 (0) | 123 (93 - 186) | 161 (127.8 - 195.8) | 117 (93 - 174) | 0.633 |

APE: acute pulmonary embolism; IQR: interquartile range; INR: international normalized ratio; CRP: c-reacted protein; WBCC: white blood cell count; LDH: lactate dehydrogenase; ALT: alanine aminotransferase; AST: aspartate transaminase; Cr: Creatinine; PaCO2: arterial partial pressure of carbon dioxide; PaO2: arterial oxygen partial pressure; FiO2: fraction of inspired oxygen.
**Table 3.** Diagnostic performance of different D-dimer cut-offs and Wells score for the diagnosis of APE.

|                                | N of cases (%) with values higher than the cut-off | RR (CI95%) for the confirmed diagnosis of APE | P value |
|--------------------------------|---------------------------------------------------|-----------------------------------------------|---------|
| D-dimer (standard cut-off: 243 ng/mL) | 36 (87.8%)                                         | 0.97 (0.23 - 16.22)                           | 0.977   |
| D-dimer (Age adjusted: patients’ age x 5) | 34 (82.93%)                                        | 1.44 (0.32 - 24.77)                           | 0.711   |
| D-dimer (cut-off: ROC CURVE best discriminating value: 2454 ng/mL) | 14 (34.15%)                                         | 3.21 (0.92 - 13.97)                           | 0.073   |
| Wells score (>2: likely)                | 6 (14.63%)                                         | 0.83 (0.05 - 3.67)                            | 0.851   |

APE: acute pulmonary embolism; RR: relative risk; CI95%: 95% confidence interval.